Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anesiva, Inc.
Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
February 29th, 2008
Anesiva, Inc. (NASDAQ:ANSV) and Sigma-Tau SpA have announced an agreement granting an exclusive license to Sigma-Tau for the marketing and distribution of Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system in six European countries: Italy, France, Germany, Netherlands, Belgium and Luxembourg. Under the terms of the agreement, Sigma-Tau will oversee all necessary regulatory filings, and will be responsible for all marketing and sales of Zingo in their territory. "In Sigma-Tau, we have selected an experienced partner that can quickly and effectively maximize the Zingo opportunity in Europe and we look forward to an excellent...
Source: Health Business Week (2008-02-29)
|
